Regeneron Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Regeneron Pharmaceuticals kazanç ve gelirin sırasıyla yıllık 10% ve 7.7% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 10.3% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 15.2% olacağı tahmin edilmektedir.

Anahtar bilgiler

10.0%

Kazanç büyüme oranı

10.30%

EPS büyüme oranı

Biotechs kazanç büyümesi	23.5%
Gelir büyüme oranı	7.7%
Gelecekteki özkaynak getirisi	15.16%
Analist kapsamı	Good
Son güncelleme	10 Mar 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Regeneron Pharmaceuticals Inc. (REGN): The Biotech Stalwart – Defensive Growth Amid Biosimilar Headwinds in 2026.

Mar 03Regeneron (REGN) is currently positioned as a defensive titan in the biotechnology sector, trading at $790.76 as of the March 2, 2026, close. While the broader healthcare index has faced pressure from regulatory pricing debates, Regeneron has demonstrated relative strength, maintaining a 1.2% year-to-date gain following a robust Q4 2025 earnings beat in late January.

Regeneron: Expect Double-Digit Growth In 2026

Jan 31

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Nov 19

Regeneron Pharmaceuticals' (NASDAQ:REGN) Anemic Earnings Might Be Worse Than You Think

Nov 09

Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025

Feb 04

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:REGN - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2028	18,619	5,875	5,909	7,045	19
12/31/2027	17,219	5,223	5,145	6,227	24
12/31/2026	15,630	4,397	4,195	5,230	26
12/31/2025	14,343	4,505	3,765	4,979	N/A
9/30/2025	14,248	4,578	3,881	5,071	N/A
6/30/2025	14,214	4,459	3,556	4,744	N/A
3/31/2025	14,086	4,499	2,962	3,953	N/A
12/31/2024	14,202	4,413	3,539	4,421	N/A
9/30/2024	13,847	4,655	3,319	4,247	N/A
6/30/2024	13,489	4,322	3,184	4,071	N/A
3/31/2024	13,100	3,858	3,930	4,739	N/A
12/31/2023	13,117	3,954	3,668	4,594	N/A
9/30/2023	13,097	3,991	4,359	5,224	N/A
6/30/2023	12,671	4,299	3,004	4,739	N/A
3/31/2023	12,370	4,183	2,527	4,281	N/A
12/31/2022	12,173	4,338	3,398	5,015	N/A
9/30/2022	13,710	5,370	4,148	5,668	N/A
6/30/2022	14,227	5,687	7,869	8,452	N/A
3/31/2022	16,508	7,934	7,936	8,515	N/A
12/31/2021	16,072	8,075	6,529	7,081	N/A
9/30/2021	13,543	6,996	5,381	5,940	N/A
6/30/2021	12,384	6,205	1,694	2,272	N/A
3/31/2021	9,198	4,004	2,029	2,589	N/A
12/31/2020	8,497	3,513	2,004	2,618	N/A
9/30/2020	7,938	3,156	1,582	2,175	N/A
6/30/2020	7,387	2,984	2,425	2,986	N/A
3/31/2020	7,013	2,279	1,706	2,231	N/A
12/31/2019	6,558	2,116	2,000	2,430	N/A
9/30/2019	6,622	2,144	N/A	2,371	N/A
6/30/2019	6,542	2,069	N/A	2,267	N/A
3/31/2019	6,572	2,428	N/A	2,473	N/A
12/31/2018	5,146	2,444	N/A	2,195	N/A
9/30/2018	6,365	1,798	N/A	2,033	N/A
6/30/2018	6,203	1,591	N/A	1,995	N/A
3/31/2018	6,065	1,428	N/A	1,570	N/A
12/31/2017	5,872	1,199	N/A	1,307	N/A
9/30/2017	5,517	1,278	N/A	1,118	N/A
6/30/2017	5,236	1,155	N/A	1,354	N/A
3/31/2017	4,979	963	N/A	1,784	N/A
12/31/2016	4,860	896	N/A	1,486	N/A
9/30/2016	4,732	797	N/A	1,377	N/A
6/30/2016	4,649	743	N/A	1,619	N/A
3/31/2016	4,435	741	N/A	1,477	N/A
12/31/2015	4,104	636	N/A	1,331	N/A
9/30/2015	3,808	571	N/A	1,247	N/A
6/30/2015	3,396	444	N/A	519	N/A
3/31/2015	3,063	346	N/A	597	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: REGN 'nin tahmini kazanç büyümesi (yıllık 10% ) tasarruf oranının ( 3.4% ) üzerindedir.

Kazançlar ve Piyasa: REGN şirketinin kazançlarının (yıllık 10% ) US pazarından (yıllık 15.7% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: REGN şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: REGN şirketinin gelirinin (yıllık 7.7% ) US pazarından (yıllık 10.4% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: REGN şirketinin gelirinin (yıllık 7.7% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: REGN 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 15.2 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/03/10 13:50
Gün Sonu Hisse Fiyatı	2026/03/10 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, raporlarımızı nasıl kullanacağınız konusunda kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Regeneron Pharmaceuticals, Inc. 51 Bu analistlerden 26, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Jasper Hellweg	Argus Research Company
Brian Skorney	Baird
Eliana Merle	Barclays

Regeneron Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates increase by 15%

Price target decreased by 7.4% to US$738

Price target decreased by 7.0% to US$797

Consensus EPS estimates fall by 15%

Price target decreased by 8.6% to US$808

Recent updates

Regeneron Pharmaceuticals Inc. (REGN): The Biotech Stalwart – Defensive Growth Amid Biosimilar Headwinds in 2026.

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Positive CHMP Opinion for Dupixent in Treating Chronic Spontaneous Urticaria in Children Aged 2 to 11 Years

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent (Dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (Afrs)

Independent Director notifies of intention to sell stock

Regeneron Pharmaceuticals, Inc. Announces Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva

Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy

Regeneron Pharmaceuticals, Inc. Announces Upcoming Presentations from Its Ophthalmology Portfolio and Pipeline At the Virtual Angiogenesis Annual Meeting on February 7, 2026

Fourth quarter dividend of US$0.94 announced

Full year 2025 earnings: EPS exceeds analyst expectations

Regeneron: Expect Double-Digit Growth In 2026

Anavex Life Sciences Corp Appoints Dr. Wolfgang Liedtke as Senior Vice President, Global Head of Neurology

Regeneron Pharmaceuticals, Inc. to Report Q4, 2025 Results on Jan 30, 2026

Independent Director exercised options to buy US$2.3m worth of stock.

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in Japan for Children Aged 6 to 11 Years with Bronchial Asthma

Alvotech and Teva Pharmaceuticals Reach a Settlement and License Agreement with Regeneron Pharmaceuticals Inc

Co-Founder exercised options and sold US$23m worth of stock

Regeneron Pharmaceuticals, Inc. Announces Lynozyfic Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

Executive VP exercised options and sold US$2.3m worth of stock

Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Approves Dupixent (Dupilumab) for the Treatment of Moderate-To-Severe Chronic Spontaneous Urticaria (CSU)

Regeneron Pharmaceuticals Announces FDA Approval Of EYLEA HD Injection 8 Mg For Treatment Of Macular Edema Following Retinal Vein Occlusion And Monthly Dosing Across Approved Indications

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

European Commission Approves the Pd-1 Inhibitor Libtayo of Regeneron Pharmaceuticals, Inc

Upcoming dividend of US$0.88 per share

Regeneron Pharmaceuticals' (NASDAQ:REGN) Anemic Earnings Might Be Worse Than You Think

Regeneron Pharmaceuticals, Inc. Announces Detailed Positive Phase 2 Trial Results Evaluating Two Novel Investigational Factor Xi Antibodies - Regn7508cat and Regn9933a2

Insider exercised options and sold US$2.2m worth of stock

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Regeneron Pharmaceuticals, Inc. announces Quarterly dividend, payable on December 05, 2025

Consensus EPS estimates increase by 15%

Regeneron Pharmaceuticals, Inc. Announces European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion for Libtayo (Cemiplimab)

Regeneron Pharmaceuticals, Inc. Announces Updated Data for Their Investigational Gene Therapy Db-Oto for Profound Genetic Hearing Loss

Regeneron Pharmaceuticals, Inc. Announces That the U.S. Food and Drug Administration Approves the PD-1 Inhibitor Libtayo(Cemiplimab-Rwlc) as an Adjuvant Treatment for Adult Patients

Regeneron Pharmaceuticals, Inc. to Report Q3, 2025 Results on Oct 28, 2025

U.S. Food and Drug Administration Approves Evkeeza (Evkeeza-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. and Sanofi Announces That European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) Adopts Positive CHMP Opinion

Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva, Demonstrating That Garetosmab Prevents Greater Than 99% of Abnormal Bone Formation

Regeneron Pharmaceuticals, Inc. Announces Five-Year Follow-Up Results on Overall Survival from the Phase 3 Empower-Lung 3 Trial

Regeneron Pharmaceuticals, Inc. Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-In-Class Antibody-Blockers of Cat and Birch Allergies

Regeneron Pharmaceuticals, Inc. Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis

Regeneron Pharmaceuticals Announces FDA Review Extension for EYLEA HD® Prefilled Syringe and Expanded Indications

Upcoming dividend of US$0.88 per share

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Regeneron Pharmaceuticals, Inc. Declares A Cash Dividend on the Common Stock and Class A Stock, Payable on September 3, 2025

Regeneron Pharmaceuticals, Inc. Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myelomac

Regeneron Pharmaceuticals, Inc.(NasdaqGS:REGN) dropped from Russell 3000 Growth Index

Regeneron Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 01, 2025

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Dupixent (Dupilumab) for the Treatment of Adult Patients with Bullous Pemphigoid

Price target decreased by 7.4% to US$738

Regeneron Pharmaceuticals, Inc. Announces Interim Results from Ongoing Phase 2 Cloud Ridge Trial Confirm Potential to Improve the Quality of Semaglutide (Glp-1 Receptor Agonist)-Induced Weight Loss by Preserving Lean Mass

Investor sentiment deteriorates as stock falls 17%

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Phase 3 Trial, AERIFY-1, Evaluating the Investigational Use of itepekimab in Adults

Regeneron Pharmaceuticals, Inc. Announces Initial Results from Two Cohorts of the Phase 1B Linker-Mm2 Trial Evaluating Linvoseltamab in Combination with Two Different Proteasome Inhibitors

Undisclosed acquirer proposed to acquire 23andMe Holding Co. (OTCPK:MEHC.Q) for approximately $260 million.

Upcoming dividend of US$0.88 per share

Price target decreased by 7.0% to US$797

Consensus EPS estimates fall by 15%

Regeneron Pharmaceuticals, Inc. Announces 24 Abstracts on Dupixent (Dupilumab) Clinical Data and Real-World Analyses in Respiratory Diseases

Price target decreased by 8.6% to US$808

Regeneron Pharmaceuticals, Inc. Declares Cash Dividend on the Common Stock and Class A Stock, Payable on June 6, 2025

First quarter 2025 earnings: EPS in line with expectations, revenues disappoint

Regeneron Pharmaceuticals, Inc. Announces Approval in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Provides Update on EYLEA HD®? (aflibercept) Injection 8 mg Supplemental Biologics License Application

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Accepts EYLEA HD (aflibercept) Injection 8 mg

Biocon Biologics Ltd Announces Settlement and License Agreement with Regeneron

Regeneron: Still A Biotech Juggernaut

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2025

Dupixent And EYLEA Will Open New Therapeutic Frontiers

Regeneron: Market Overlooks A Resilient Franchise And Robust Free Cash Flow

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Ministry of Health, Labour and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab)

Regeneron Pharmaceuticals, Inc. to Report Q1, 2025 Results on Apr 29, 2025